Antibody-Drug Conjugates (ADCs) often fail because the drug gets to the right tissue, but misses its target. It’s not enough to just seek the concentration of your ADC in the tissue, you need to know its exact location to predict efficacy and move your development program forward with confidence. In this webinar, renowned scientists and industry thought leaders, Troy Voelker, and Corinne Ramos, outline a holistic bioanalytical strategy for your ADC, incorporating traditional bioanalysis with spatial bioanalysis to reveal decision-making data about how your ADC engages with the complex microenvironment.

 

Join us to learn step by step how to derisk your ADC program with guidance on assessing:

 

Troy Voelker

Senior Laboratory Director

Aliri Bioanalysis (CO, USA)

Troy is a bioanalytical scientist with a specialization in oligonucleotides and has 20+ years of experience supporting the drug developers with regulatory-ready data. He received a PhD in XX from the Human BioMolecular Research Institute (CA, USA). He is also a member of the AAPS Oligonucleotide Discussion Group and regularly contributes to the advancement of the industry through featured presentations and scientific posters at top bioanalytical conferences like the American Association of Phamaceutical Scientists (AAPS) PharmSci 360.

 

Corinne Ramos

R&D Director

Aliri Bioanalysis (CO, USA)

Corinne is a biomarker expert with 25+ years of experience in clinical assay/biomarker development validation and molecular oncology and imaging in oncology/diagnostics. She received a PhD in Molecular Biology from the University Paul Sabatier (Toulouse, France) and an MBA from the Johns Hopkins University-Carey Business School (Washington DC, USA). Corinne has published numerous scientific papers, given presentations at industry-leading conferences like European Bioanalysis Forum (EBF) and is well-known for her work integrating AI with spatial-omics to predict patient outcomes.